MedTrace Logo

The Effect of Pregnancy on the PK of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters

NCT01251601 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-02-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether pregnancy affects the blood concentrations of raltegravir by comparing the second trimester and third trimester drug concentrations with post partum.

Conditions

  • HIV
  • Pregnancy

Interventions

OTHER

Pharmacokinetics

Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum

Sponsors & Collaborators

Principal Investigators

  • Angela DM Kashuba, PharmD · UNC Chapel Hill

  • Kristine B Patterson, MD · UNC Chapel Hill

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-09-30
Completion
2011-09-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01251601 on ClinicalTrials.gov